Farinelli Denise G, Oliveira Kelly C, Hayashi Lilian F, Kater Claudio E
Adrenal and Hypertension Unit, Division of Endocrinology and Metabolism, Department of Medicine at the Federal University of São Paulo School of Medicine (EPM/UNIFESP), São Paulo, SP, Brazil.
Adrenal and Hypertension Unit, Division of Endocrinology and Metabolism, Department of Medicine at the Federal University of São Paulo School of Medicine (EPM/UNIFESP), São Paulo, SP, Brazil.
Endocr Pract. 2023 Dec;29(12):986-993. doi: 10.1016/j.eprac.2023.09.007. Epub 2023 Sep 20.
To determine the frequency of "invalid" 1-mg overnight dexamethasone (Dex) suppression tests (DSTs) (1-mg DST) on a large series of patients investigated for hypercortisolism and examine the interference of substances and clinical conditions that may explain low serum Dex levels.
A retrospective analysis of 1300 Dex-controlled 1-mg DST applied to patients screened for Cushing syndrome or mild autonomous cortisol secretion in a single center for which there were identified invalid tests and distinctive characteristics that may have interfered with the outcome.
Among all tests, 146 (11.2%) were considered invalid (serum Dex levels <140 ng/dL, 36 [24.7%] of which were undetectable [<19.5 ng/dL]). In the Dex-undetectable group, 17% failed to take Dex correctly, 25% were on glucocorticoids (GCs), and 20% were on anticonvulsants and moderate CYP3A4 inducers. In the remaining 110 tests (serum Dex 20-140 ng/dL), 6.5% did not take Dex or were using GC, 22% were on anticonvulsants or CYP3A4 inducers, and another 13% had previous gastrointestinal tract abnormalities impairing drug absorption.
Inappropriately low serum Dex levels during the 1-mg DST may lead to false-positive results. This is associated with recurrent use of CYP3A4-inducing drugs and/or gastrointestinal abnormalities. When serum Dex is undetectable, the key reason is failure to take the medication or the use of GC (when cortisol is suppressed). Simultaneous measurement of serum cortisol and Dex allows for DST validation, improving its accuracy and avoiding unnecessary repetitions. Adherence to verbal/written recommendations and actual use of medication are critical for interpreting the test.
确定在一大系列因皮质醇增多症接受检查的患者中“无效”的1毫克过夜地塞米松(Dex)抑制试验(DST)(1毫克DST)的频率,并检查可能解释血清Dex水平低的物质和临床状况的干扰因素。
对在单一中心筛查库欣综合征或轻度自主性皮质醇分泌的患者应用的1300次Dex对照1毫克DST进行回顾性分析,确定其中无效的试验以及可能干扰结果的独特特征。
在所有试验中,146次(11.2%)被认为无效(血清Dex水平<140纳克/分升,其中36次[24.7%]检测不到[<19.5纳克/分升])。在Dex检测不到的组中,17%未正确服用Dex,25%正在使用糖皮质激素(GCs),20%正在使用抗惊厥药和中度CYP3A4诱导剂。在其余110次试验(血清Dex为20 - 140纳克/分升)中,6.5%未服用Dex或正在使用GC,22%正在使用抗惊厥药或CYP3A4诱导剂,另有13%既往有胃肠道异常影响药物吸收。
1毫克DST期间血清Dex水平异常低可能导致假阳性结果。这与反复使用CYP3A4诱导药物和/或胃肠道异常有关。当血清Dex检测不到时,关键原因是未服药或使用GC(当皮质醇被抑制时)。同时测量血清皮质醇和Dex可验证DST,提高其准确性并避免不必要的重复。遵守口头/书面建议以及实际用药情况对于解释该试验至关重要。